Core Insights - Aclarion, Inc. is participating in the State of Spine Surgery Think Tank to showcase its NOCISCAN platform, which utilizes biomarkers and AI to identify chronic low back pain [1][2] - Dr. Kris Radcliff will present the NOCISCAN platform, emphasizing its innovative approach to objectively identify discogenic pain [2] - The conference highlights the increasing interest in NOCISCAN's clinical and commercial value, as noted by Aclarion's Chief Strategy Officer [3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, leveraging Magnetic Resonance Spectroscopy (MRS) and AI algorithms [6] - NOCISCAN is the first evidence-supported SaaS platform designed to noninvasively distinguish between painful and nonpainful lumbar discs [4][6] - The platform quantifies chemical biomarkers associated with disc pain, providing critical insights when used alongside other diagnostic tools [4][6] Market Context - Chronic low back pain affects approximately 266 million people globally, representing a significant healthcare challenge [4] - The integration of NOCISCAN into clinical practice aims to develop personalized and effective surgical strategies for patients [2][3]

Core Viewpoint - Aclarion, Inc. announced the addition of UHealth — University of Miami Health System as a trial site for the CLARITY study, which aims to demonstrate the clinical and economic value of its Nociscan technology in spine surgery [1][2]. Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][6]. - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][6]. CLARITY Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain [3]. - The trial will randomize patients in a 1:1 ratio between surgeons blinded to Nociscan results and those unblinded, with the primary endpoint being the change in back pain measured on a 100mm VAS at 12 months [3]. - UHealth joins other prestigious institutions like Johns Hopkins Medicine and Northwestern Medicine as a trial site [2][3]. Clinical Significance - Chronic low back pain affects approximately 266 million people globally, highlighting the need for effective diagnostic and treatment solutions [4]. - Nociscan aims to improve surgical outcomes by providing critical insights into the location of low back pain through the analysis of chemical biomarkers [4][8]. Research and Development - The CLARITY trial represents a unique opportunity to advance the spine industry and showcase the research capabilities of the University of Miami [2][7]. - Aclarion's technology leverages Magnetic Resonance Spectroscopy (MRS) to optimize clinical treatments for chronic low back pain [6][7].

Core Insights - VEON Ltd. has opened a new headquarters for Beeline Uzbekistan in Tashkent IT Park, housing around 2,000 employees and various digital service teams [1][2][4] - The relocation signifies VEON's commitment to investing in Uzbekistan's digital future and enhancing the provision of digital services in Central Asia [2][5] Company Developments - Beeline Uzbekistan serves 8.2 million customers with mobile connectivity and has 7.6 million total monthly active users across its digital services [6] - The digital portfolio includes financial services application BeePul, streaming application Kinom, and super-app Hambi, showcasing a diverse range of offerings [6] - Beeline Uzbekistan reported 9.5 million monthly active digital users in Q1 2025, indicating strong demand for its digital services [4] Industry Context - Uzbekistan is positioning itself as a regional digital hub through its Digital Uzbekistan 2030 strategy, aiming to create a thriving digital economy [3] - The government welcomes partnerships with companies like VEON to support innovation and attract global investment [3] - VEON has been investing in Uzbekistan's telecommunications and digital infrastructure since 2006, expanding its services beyond traditional connectivity [5]

Core Insights - Aclarion, Inc. announced the addition of Keck Medical Center of USC as a site for the CLARITY trial, aimed at demonstrating the clinical and economic value of Nociscan in spine surgery [1][2] - The CLARITY trial will evaluate 300 patients undergoing surgical treatment for discogenic low back pain, with a primary endpoint of measuring changes in back pain at 12 months [3][4] Company Overview - Aclarion is a healthcare technology company utilizing biomarkers and AI algorithms to assist physicians in identifying chronic low back pain [1][6] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][6] Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving multiple high-volume sites across the US, including notable institutions like Johns Hopkins Medicine and Northwestern Medicine [2][3] - The trial will randomize patients in a 1:1 ratio between surgeons who are blinded and unblinded to Nociscan results [3] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting a significant healthcare challenge [4] - Aclarion's Nociscan aims to improve surgical outcomes by providing insights into the sources of low back pain through advanced diagnostic techniques [4][7]

Nociscan Solution & Market Opportunity - Nociscan leverages MR Spectroscopy and Augmented Intelligence for patients with pain of spinal origin [9] - Nociscan labels each disc as painful or pain free based upon a biochemical signal and correlation with provocative discography, leading to lower cost, better outcomes, and higher value care [14] - The U S low back & neck pain market represents an ultimate market of $135 billion [17] - The U S lumbar spine market (fusion & non-fusion surgery plus presurgical care) represents an expansion market of $40 billion [16] - The U S lumbar fusion & disc replacement market represents an actionable market of $10 billion [17] Foundational Science & Technology - Elevated Lactate is associated with Nociceptor Activation, Excessive Cellular Demand, Cell Death and Reduced PG Synthesis [23] - Spectroscopy analyzes the chemical composition of tissue, transforming raw spectral data into clear biomarkers [26] - Nociscan uses six ratios for each disc, with pain markers in the numerator and structural integrity markers in the denominator, leveraging AI for major advancements [30, 33] Clinical and Economic Evidence - MRS (NOCI+/–) compared to PD (P/NP) with an accuracy of 87%, sensitivity of 100%, and specificity of 80% [47] - The positive predictive value (PPV) in herniated discs, and negative predictive value (NPV) in non-herniated discs, were 100% [47] - MRS with the Nociscan diagnostic algorithm demonstrates cost-effectiveness dominance over PD for identifying CLBP surgical candidates, with annualized US savings estimated between $283 million and $441 million [51, 53] Intellectual Property & Availability - Aclarion has 23 issued U S Patents and 13 Pending Patent Applications [39, 38] - Over 1,100 Commercial Nociscans have been performed [97]

Core Viewpoint - Aclarion, Inc. has announced the Texas Back Institute as a new site for its pivotal CLARITY trial, which aims to demonstrate the clinical and economic value of its Nociscan technology in spine surgery [1][4]. Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][6]. - The company's Nociscan platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and nonpainful lumbar discs [4][7]. CLARITY Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain [3]. - The trial will randomize patients in a 1:1 ratio between surgeons blinded to Nociscan results and those unblinded, guiding surgical treatment decisions [3]. - The primary endpoint is the change in back pain measured on a 100mm Visual Analog Scale (VAS) at 12 months compared to baseline [3]. Texas Back Institute's Role - Texas Back Institute is recognized for its excellence in research and has participated in various studies related to spine treatments [2][4]. - The institute's involvement in the CLARITY trial is expected to enhance the study's credibility and align with its patient population [2][4]. Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge it presents [4]. - Aclarion's Nociscan aims to improve surgical outcomes by providing critical insights into the sources of low back pain through advanced diagnostic techniques [4][7].

Core Insights - Aclarion, Inc. announced the addition of Advocate Aurora Research Institute as a site for the CLARITY trial, which aims to demonstrate the clinical and economic value of its Nociscan platform in spine surgery [1][4][5] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][5][8] - The Nociscan platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [5][8] CLARITY Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain [4] - The trial will randomize patients at a 1:1 ratio between surgeons blinded to Nociscan results and those unblinded, with the primary endpoint being the change in back pain measured on a 100mm VAS at 12 months [4][5] - The principal investigator is Dr. Nicholas Theodore from Johns Hopkins Medicine [4] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting a significant healthcare challenge [5] - Traditional imaging methods often fail to clearly identify the source of pain, which Nociscan aims to address by providing insights into disc pain [5][8]

Core Insights - Aclarion, Inc. has established a commercial agreement with the Spine Institute of Louisiana (SIL) to introduce Nociscan, a technology aimed at identifying chronic low back pain [1][2][4] - Nociscan is now available at 17 commercial centers across eight states and four countries, enhancing its accessibility [3] - The technology utilizes Magnetic Resonance Spectroscopy (MRS) to help physicians distinguish between painful and nonpainful discs in the lumbar spine, addressing a significant global healthcare issue affecting approximately 266 million people [4][5] Company Overview - Aclarion is a healthcare technology company that leverages biomarkers and proprietary AI algorithms to optimize clinical treatments, specifically targeting chronic low back pain with its Nociscan platform [5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively assist physicians in identifying the source of low back pain, demonstrating a 97% surgical success rate when treating identified pain-positive discs [4][5] Industry Context - Chronic low back pain (cLBP) is a prevalent global healthcare challenge, with a significant number of individuals suffering from degenerative spine disease [4] - The introduction of Nociscan at SIL aligns with the institute's commitment to innovative and less invasive treatment techniques for chronic low back pain [2]

Core Insights - Aclarion, Inc. is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][4] - The company will present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025, highlighting recent initiatives aimed at enhancing value [2][1] - Aclarion has released an updated investor presentation available on its website [3] Company Overview - Aclarion leverages Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments for chronic low back pain [4] - The company's primary product, Nociscan, is a SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4] - Nociscan utilizes cloud technology to analyze MRS data from MRI machines, extracting chemical biomarkers associated with disc pain to provide insights for treatment optimization [4]

Company Overview - Aclarion, Inc. is a healthcare technology company focused on leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians in identifying the location of chronic low back pain [1][3] - The company is addressing the chronic low back pain market with its product Nociscan, which is the first evidence-supported SaaS platform designed to noninvasively help physicians distinguish between painful and non-painful discs in the lumbar spine [3] Product Details - Nociscan utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments [3] - The platform receives MRS data from MRI machines and processes it in the cloud to extract and quantify chemical biomarkers associated with disc pain [3] - Nociscan provides critical insights into the location of a patient's low back pain, enabling physicians to optimize treatment strategies [3] Upcoming Events - Aclarion will present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025, at 12:30 PM ET, hosted by CEO Brent Ness [1][2] - The presentation will be accessible via a live webcast, and 1x1 investor meetings can be scheduled at the conference venue [2]